| Name | ND2158 | CAS# | 1388896-07-8 | |
|---|---|---|---|---|
| Price | $Inquiry/100mg $Inquiry/250mg $Inquiry/1g | Purity | 98.0% | |
| Stocking Period |
3 Day | Stock | 3 | |
| Product Webpage: | https://www.dcchemicals.com/product_show-nd2158.html | |||
| Detail
Product Information
ND2158 (ND-2158) is a highly potent and selective IRAK4 inhibitor with IC50 of 1.3 nM; ND2158 demonstrates high selectivity against 334 kinases, and >1000-fold over IRAK1. ND2158 blocked TNF production, collagen-induced arthritis, and gout formation in mice, suppressed LPS-induced TNF production, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. IRAK4 inhibition promoted killing of ABC DLBCL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway. In ABC DLBCL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199. |